Overview

Pasireotide Treatment for Neuroendocrine Tumor

Status:
Withdrawn

Trial end date:
2016-06-01

Target enrollment:

Participant gender:

Summary

Pasireotide binds to somatostatin receptors sst2 and sst5, which can lead to significant hyperglycemia. The investigators would like to administer pasireotide as a treatment for refractory hypoglycemia in the setting of metastatic insulin-producing pancreatic neuro-endocrine tumor.

Phase:

Phase 4

Details

Lead Sponsor:

University of Maryland
University of Maryland, Baltimore

Collaborator:

Novartis

Treatments:

Diazoxide
Insulin
Insulin, Globin Zinc
Pasireotide
Somatostatin